KN5601

Phase 1Biologic

TThe Children's Hospital of Zhejiang University School of Medicine

KN5601 is one of 59 biologic programs targeting Rheumatic Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatic DiseaseRecruiting

Rheumatic DiseasePhase 1

Recruiting

Competition

Competitive Landscape

63 competitors in Rheumatic Disease

#DrugCompanyPhaseTrials

Voltaren

Aleve

MS Contin

HHikma Pharmaceuticals LLC

Approved

—4

Indocin

CCosette Pharmaceuticals, Inc.

Advil

Decadron

AAspen Global Incorporated

Approved

—7

Clinoril

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—8

Ansaid

PPharmacia and Upjohn

Approved

—9

Oruvail

WWyeth-Lederle Vaccines

Approved

—10

Celebrex

PPhiladelphia Eye Associates

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Rheumatic Disease

NCT07490041

Clinical

Trials by Indication[1]

Rheumatic Disease1 trial

Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases

Recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·Phase 1·NCT07490041·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for KN5601. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KN5601 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KN5601. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Children's Hospital of Zhejiang University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: TThe Children's Hospital of Zhejiang University School of Medicine

KN5601

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Rheumatic Disease1 trial

References

Drug Info

Quick Facts

Related News